Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

Adverse events of grade 3 or higher occurred in 52.8% of the patients in the trastuzumab deruxtecan group and in 44.4% of those in the chemotherapy group. Adjudicated interstitial lung disease or ...

The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain ... neutropenia (low levels of a type of white blood cells), fatigue, and anemia. Interstitial lung ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial ...

Opens in a new tab or window Trastuzumab deruxtecan (Enhertu ... with no new safety signals. However, interstitial lung disease (ILD)/pneumonitis "remains an important identified safety risk ...

The findings, from an international clinical trial led by Dana-Farber Cancer Institute researchers, reinforce earlier findings of the benefits of the drug – trastuzumab deruxtecan (T-DXd), an ...

Trastuzumab deruxtecan (T-DXd ... percent of the BM cohort and 12.9% of the non-BM cohort reported interstitial lung disease/pneumonitis, and 5 events co-occurred with opportunistic infection ...

Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab ...

The safety profile in HERTHENA-Lung02 was consistent with that observed for patritumab deruxtecan in previous lung cancer trials. The majority of interstitial lung disease (ILD) events were low ...